[Correlation of adiponectin in patients with type 2 diabetes with nonalcoholic fatty liver disease depending on transaminases level].

We studied the changes of serum adiponectin and it correlations in patients with type 2 diabetes (T2D) and NAFLD related to transaminases levels. Serum adiponectin levels were significantly lower in the increased ALT group than in the normal ALT and control group. After adjusting for age, sex, and adiposity adiponectin was significantly correlated in control group with fasting insulin, and insulin resistance by homeostasis model of assessment (HOMA-IR); in the normal ALT group with HDL-cholesterol , triglycerides, fasting insulin and HOMA-IR; in the elevated transaminases group with ALT, fasting insulin and HOMA-IR. Step-wise multiple linear regression analyses demonstrated that in NAFLD with normaltransaminases, independent predictors of adiponectin was HOMA-IR, triglycerides, BMI and duration of T2D. In NAFLD with elevated transaminases, adiponectin was associated with HOMA-IR, BMI, male genderand ALT.

[Effect of probiotics on proinflammatory cytokines level in patients with type 2 diabetes and nonalcoholic fatty liver disease].

We examined 72 patients with T2D and NAFLD. All patients divided by us on the way of therapy into 2 groups. The main group (n = 45) received oral antidiabetic therapy and multiprobiotic "Symbiter" within 30 days. Patients of comparison group (n = 27) received only hypoglycemic drugs. Also in each group we identified patients with normal and elevated level of transaminases. We observed 1.5-2 times increasing of cytokines in patients with NAFLD and elevated transaminase levels compared to patients with normal transaminase levels. We noted statistically significant reduction of proinflammatory cytokines in plasma, after 30 days of therapy, in patients with elevated levels of transaminases. In particular, the level of IL-6 decreased on 30.9% (P < 0.001), IL-8 - 19.9% (P = 0.001), TNF-alpha - 13.4% (P < 0.001), IL-1beta - 17.9% (P < 0.001) and IFN-gamma on 18.7% (P < 0.001) respectively. In patients with normal levels transaminases and NAFLD were significantly decreased only TNF-alpha on 15.1% (P = 0.003) and IL-8 on 15.2% (P = 0.017). Significant changes in cytokines levels in patients of comparative group we don't observed. Probiotics can be recommended for use in patients with different stages of NAFLD and T2D as an adjunct to standard treatment regimens because it decreases manifestations of low-grade systemic inflammatory response.

[Liver stiffness in animals with glutamate-induced obesity (according to shear wave ultrasound elastography)].

We studied changes of liver stiffness measured by SWE in animals with glutamate-induced obesity (GIO). We noted significant increase of LS on 63.6% compared to intact rats (P < 0.001). Histologically confirmed non-alcoholic steatosis diagnosed in 93.3% of animals with obesity. The AUROC of SWE for in animals with GIO was 0.983 (95% CI 0.955-0.999; P < 0.001). The optimal LS cutoff point for the prediction of steatosis were > 6.25 kPa, with sensitivity, specificity, PPV and NPV 86.6; 100; 100 and 93.7% respectively.

[Phytoconcentrates "dzherelo" and "lizorm" in therapy of autoimmune thyroiditis]. / Fitokontsentraty "dzherelo" ta "lizorm" v likuvanni autoimunnoho tyreoïdytu.

Treatment of patients with autoimmune thyroiditis with phytoconcentrates dzherelo and lizorm has been shown to improve the patients general well-being, alleviate gross manifestations of the condition, impede the development of the autoimmune process. The above therapy is well-tolerated, has no hepato-/nephrotoxic effect, causes no functional/structural disturbances, and does not affect the sizes of the thyroid gland. The phytoconcentrates dzherelo and lizorm can be recommended as treatment of autoimmune thyroiditis (euthyroid state, mild hypothyroisis, in those settings where activity of the autoimmune process is not very high.

[Laser therapy in diabetes mellitus]. / Lazeroterapiia pry tsukrovomu diabeti.

Diabetic patients have been shown to derive great benefit from treatment with laser therapy as evidenced by experience gained with its use over many years. Laser therapy promotes compensation, has an antiatherogenic, antioxidant, immunomodulating effects, improves microcirculation, myocardial contractility and performance capability.